Tuesday, February 1, 2011
Sinovac Biotech Ltd., of Beijing, submitted applications to the Chinese SFDA for clinical trials of its pneumococcal polysaccharide vaccines. Preclinical studies showed favorable safety and efficacy profiles in animals.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.